MX2019014658A - Anticuerpos humanizados que reconocen la alfa-sinucleina. - Google Patents

Anticuerpos humanizados que reconocen la alfa-sinucleina.

Info

Publication number
MX2019014658A
MX2019014658A MX2019014658A MX2019014658A MX2019014658A MX 2019014658 A MX2019014658 A MX 2019014658A MX 2019014658 A MX2019014658 A MX 2019014658A MX 2019014658 A MX2019014658 A MX 2019014658A MX 2019014658 A MX2019014658 A MX 2019014658A
Authority
MX
Mexico
Prior art keywords
synuclein
humanized antibodies
recognize alpha
alpha
recognize
Prior art date
Application number
MX2019014658A
Other languages
English (en)
Inventor
Saldanha Jose
S Nijjar Tarlochan
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2019014658A publication Critical patent/MX2019014658A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente solicitud describe los anticuerpos 9E4 humanizados. Los anticuerpos se unen a la alfa sinucleína humana y pueden utilizarse para la inmunoterapia de la enfermedad de cuerpos de Lewy.
MX2019014658A 2011-10-28 2014-04-25 Anticuerpos humanizados que reconocen la alfa-sinucleina. MX2019014658A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553131P 2011-10-28 2011-10-28
US201261711208P 2012-10-08 2012-10-08

Publications (1)

Publication Number Publication Date
MX2019014658A true MX2019014658A (es) 2020-02-07

Family

ID=48168610

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014005038A MX370234B (es) 2011-10-28 2012-10-26 Anticuerpos humanizados que reconocen la alfa-sinucleina.
MX2019014658A MX2019014658A (es) 2011-10-28 2014-04-25 Anticuerpos humanizados que reconocen la alfa-sinucleina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014005038A MX370234B (es) 2011-10-28 2012-10-26 Anticuerpos humanizados que reconocen la alfa-sinucleina.

Country Status (31)

Country Link
US (7) US8609820B2 (es)
EP (2) EP2771031B1 (es)
JP (4) JP5775974B2 (es)
KR (1) KR101600733B1 (es)
CN (2) CN107880123A (es)
AU (3) AU2012328530A1 (es)
BR (1) BR112014010198B1 (es)
CA (1) CA2853531C (es)
CL (1) CL2014001073A1 (es)
CO (1) CO7020875A2 (es)
CY (1) CY1120398T1 (es)
DK (2) DK3378535T3 (es)
ES (2) ES2937409T3 (es)
FI (1) FI3378535T3 (es)
HK (3) HK1201450A1 (es)
HR (2) HRP20230065T1 (es)
HU (2) HUE037811T2 (es)
IL (2) IL232264B (es)
LT (2) LT3378535T (es)
MX (2) MX370234B (es)
MY (1) MY165038A (es)
PE (1) PE20141568A1 (es)
PL (2) PL3378535T3 (es)
PT (2) PT3378535T (es)
RS (2) RS57315B1 (es)
RU (1) RU2743738C2 (es)
SG (1) SG11201401857WA (es)
SI (2) SI3378535T1 (es)
UA (1) UA116194C2 (es)
WO (1) WO2013063516A1 (es)
ZA (1) ZA201403864B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
LT3378535T (lt) 2011-10-28 2023-02-27 Prothena Biosciences Limited Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
BR112014018561A8 (pt) 2012-01-27 2017-07-11 Neotope Biosciences Ltd Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
JP2017501848A (ja) * 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
HRP20211935T1 (hr) 2016-06-02 2022-03-18 Medimmune Limited Protutijela anti-alfa-sinuklein i njihove uporabe
US20180328943A1 (en) * 2016-09-30 2018-11-15 Enzo Biochem, Inc. Immunomodulatory compositions and methods of use thereof
AU2017359944B2 (en) * 2016-11-15 2024-07-18 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
EP3548074A4 (en) 2016-12-02 2020-07-01 Prothena Biosciences Limited INFRARED ASSAY DETECTING SECONDARY ALPHA-SYNUCLEIN STRUCTURE PROFILES
EP3555127A1 (en) 2016-12-16 2019-10-23 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3049110A1 (en) 2017-01-06 2018-07-12 Abl Bio Inc. Anti-.alpha.-syn antibody and use thereof
EA039807B1 (ru) 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
JP7136790B2 (ja) * 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
EP3618870A4 (en) 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
AU2018385230B2 (en) * 2017-12-14 2022-10-13 Abl Bio Inc. Bispecific antibody to a-syn/IGF1R and use thereof
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
US20220018851A1 (en) 2018-08-09 2022-01-20 Hoffmann-La Roche Inc. Determination of parkinson's disease
TWI734279B (zh) 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
BR112021025086A2 (pt) * 2019-06-14 2022-01-25 Abl Bio Inc Anticorpo biespecífico contra a-syn/igfir e uso do mesmo
EP4400515A2 (en) 2020-04-24 2024-07-17 F. Hoffmann-La Roche AG Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
CN112710850A (zh) * 2020-12-29 2021-04-27 苏州百志生物科技有限公司 一种检测人体液中α-突触核蛋白含量的试剂盒
CN113912712B (zh) * 2021-12-15 2022-03-08 北京凯祥弘康生物科技有限公司 抗α-突触核蛋白的单克隆抗体的制备及其应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
ATE216590T1 (de) 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1531864A4 (en) 2002-05-13 2006-08-23 Alexion Pharma Inc HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS
WO2008103472A2 (en) 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
WO2004050884A2 (de) 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
CA2514153A1 (en) * 2003-01-22 2004-08-05 Takeda Pharmaceutical Company Limited Antibody and use thereof
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US7674599B2 (en) * 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
US7022550B2 (en) 2004-04-07 2006-04-04 Gelcore Llc Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2325931T3 (es) 2004-11-10 2009-09-24 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Utilizacion del analisis por citometria de flujo para optimizar las estrategias de almacenamiento en bancos de celulas para celulas cho.
EP1858928A2 (en) 2005-03-08 2007-11-28 Pharmacia & Upjohn Company LLC Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
MX2009000476A (es) * 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
EP2522729A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
KR101555068B1 (ko) 2007-03-22 2015-10-06 제넨테크, 인크. 막 결합형 ｉｇｅ에 결합하는 세포자멸성 항-ｉｇｅ 항체
UA96473C2 (ru) 2007-03-22 2011-11-10 Имклоун Ллк Жидкая стойкая композиция, которая содержит антитело imc-а12
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
EP2730659A3 (en) 2007-12-28 2016-01-13 Prothena Biosciences Limited Treatment and Prophylaxis of Amyloidosis
JP5747414B2 (ja) * 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
AU2009328505B2 (en) * 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
NZ623910A (en) 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
PL214940B1 (pl) 2009-07-31 2013-09-30 Lozano Platonoff Alberto Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
EP2366714A1 (en) * 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2581113B1 (en) 2010-06-11 2018-05-09 Kyowa Hakko Kirin Co., Ltd. Anti-tim-3 antibody
LT2593128T (lt) 2010-07-15 2018-06-25 Adheron Therapeutics, Inc. Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai
AU2011316730B2 (en) 2010-10-11 2015-12-10 Abbvie Bahamas Ltd. Processes for purification of proteins
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
US8619359B2 (en) 2011-04-27 2013-12-31 Howard Letovsky Electronic microscope filter
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
EP2726098A1 (en) 2011-06-30 2014-05-07 F.Hoffmann-La Roche Ag Anti-c-met antibody formulations
AU2012328739B2 (en) 2011-10-25 2017-11-30 Prothena Biosciences Limited Antibody formulations and methods
LT3378535T (lt) 2011-10-28 2023-02-27 Prothena Biosciences Limited Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
HUE061728T2 (hu) 2011-10-31 2023-08-28 Hoffmann La Roche Anti-IL13 antitest készítmények
BR112014018561A8 (pt) 2012-01-27 2017-07-11 Neotope Biosciences Ltd Anticorpo; ácido nucleico; célula hospedeira; composição farmacêutica; uso de um anticorpo; método para produção de um anticorpo; e método para produção de uma linhagem celular que produz um anticorpo
RU2663120C2 (ru) 2012-08-29 2018-08-01 Ф.Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
JP6234511B2 (ja) 2017-11-22
EP2771031A4 (en) 2015-03-18
HK1252895A1 (zh) 2019-06-06
NZ625624A (en) 2016-06-24
US20200024336A1 (en) 2020-01-23
JP2018046836A (ja) 2018-03-29
SI2771031T1 (en) 2018-08-31
CL2014001073A1 (es) 2014-12-19
JP5960328B2 (ja) 2016-08-02
DK2771031T3 (en) 2018-05-28
PL3378535T3 (pl) 2023-05-08
PE20141568A1 (es) 2014-11-21
BR112014010198B1 (pt) 2022-12-06
JP2015232002A (ja) 2015-12-24
CA2853531A1 (en) 2013-05-02
CA2853531C (en) 2020-03-10
CY1120398T1 (el) 2019-07-10
RU2016101137A3 (es) 2020-01-09
US8609820B2 (en) 2013-12-17
HRP20180728T1 (hr) 2018-07-27
AU2017276296A1 (en) 2018-01-18
KR20140081898A (ko) 2014-07-01
AU2017276296B2 (en) 2020-01-16
PT3378535T (pt) 2023-02-06
KR101600733B1 (ko) 2016-03-09
FI3378535T3 (fi) 2023-04-12
MY165038A (en) 2018-02-28
LT3378535T (lt) 2023-02-27
PL2771031T3 (pl) 2018-09-28
DK3378535T3 (da) 2023-01-30
AU2012328530A1 (en) 2014-06-26
US9884906B2 (en) 2018-02-06
ES2937409T3 (es) 2023-03-28
US11345749B2 (en) 2022-05-31
JP2015502341A (ja) 2015-01-22
AU2016202622B2 (en) 2017-09-14
EP2771031A1 (en) 2014-09-03
EP2771031B1 (en) 2018-04-18
CN104334184A (zh) 2015-02-04
US20210040188A1 (en) 2021-02-11
RU2016101137A (ru) 2018-11-16
HK1206637A1 (en) 2016-01-15
HRP20230065T1 (hr) 2023-03-03
JP2016208981A (ja) 2016-12-15
US20140275495A1 (en) 2014-09-18
HUE061978T2 (hu) 2023-09-28
US9556259B2 (en) 2017-01-31
US20220411486A1 (en) 2022-12-29
BR112014010198A2 (pt) 2018-08-07
ES2669395T3 (es) 2018-05-25
IL272615A (en) 2020-03-31
MX2014005038A (es) 2015-03-09
RS63930B1 (sr) 2023-02-28
MX370234B (es) 2019-12-06
IL272615B (en) 2022-04-01
CO7020875A2 (es) 2014-08-11
UA116194C2 (uk) 2018-02-26
US20180201669A1 (en) 2018-07-19
ZA201403864B (en) 2015-08-26
HUE037811T2 (hu) 2018-09-28
US10450369B2 (en) 2019-10-22
EP3378535A1 (en) 2018-09-26
RU2014121325A (ru) 2015-12-10
HK1201450A1 (en) 2015-09-04
RS57315B1 (sr) 2018-08-31
US20170240621A1 (en) 2017-08-24
EP3378535B1 (en) 2023-01-04
SI3378535T1 (sl) 2023-04-28
PT2771031T (pt) 2018-05-24
JP5775974B2 (ja) 2015-09-09
AU2016202622A1 (en) 2016-05-19
CN104334184B (zh) 2017-12-29
US10723792B2 (en) 2020-07-28
SG11201401857WA (en) 2014-09-26
LT2771031T (lt) 2018-08-27
WO2013063516A1 (en) 2013-05-02
IL232264B (en) 2020-02-27
CN107880123A (zh) 2018-04-06
JP6592059B2 (ja) 2019-10-16
IL232264A0 (en) 2014-06-30
US20130108546A1 (en) 2013-05-02
RU2743738C2 (ru) 2021-02-25

Similar Documents

Publication Publication Date Title
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
PH12014501685A1 (en) Humanized antibodies that recognize alpha-synuclein
IL268822A (en) Medical uses of anti-beta 7 monoclonal antibodies or fragments thereof
WO2015091914A3 (en) Caninized murine anti-canine pd-1 antibodies
MX2020011064A (es) Inmunoglobulinas heterodimericas.
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
AU2018256498A1 (en) Antibodies to amyloid beta
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX357193B (es) Moleculas de union anti-alfa sinucleina.
NZ724348A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
EA201400579A1 (ru) Антитела к il-36r
UA107574C2 (ru) Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
MX2016008099A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
GB201109238D0 (en) Antibodies
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
IL284367A (en) Monoclonal antibodies that uniquely bind to human TRBV9
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.